The 4th HARMONY General Assembly 2019 is organized on the 26th and 27th September in Florence, Italy. The General Assembly is a highly valuable annual meeting [only to be attended by the official HARMONY Alliance contacts] both from a substance as from a collaborative perspective.
With the first results in AML, CLL, and MM, our groups in MDS, ALL/Pediatrics, and NHL working full steam ahead, and the increasing number of datasets in the HARMONY Big Data Platform, this annual General Asssembly meeting is the perfect starting point for the second wave of HARMONY research projects. During 2 days representatives of our 80+ public and private Partners and Associated Members will listen to project update, participate in round tables engage in research-a-thon sessions organised for each of the 7 hematologic malignancies where HARMONY Partners and Associated Members are collaborating.
More information to be found in our meeting post >
Link to the current 7 HM Research Projects >
The HARMONY Alliance is a public-private European Network of Excellence, established in January 2017. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies. We currently have 53 Partners and 37 Associated Members from 22 countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
